Table 4.
Proportions of remitters/nonremitters with normal functioning before and after treatment.
| Level | Remitters |
Nonremitters |
Difference at exit |
||||||
|---|---|---|---|---|---|---|---|---|---|
| N | Within normal function entry (%) | Within normal function exit (%) | McNemar test p value | N | Within normal function entry (%) | Within normal function exit (%) | McNemar test p value | χ2 or Fisher test p value | |
| 1 | 812 | 10.2 | 80.5 | <0.0001 | 1,468 | 4.7 | 15.3 | <0.0001 | <0.0001 |
| 2 | 208 | 11.5 | 74.0 | <0.0001 | 541 | 4.4 | 15.7 | <0.0001 | <0.0001 |
| 3 | 30 | 6.7 | 60.0 | 0.0001 | 160 | 4.4 | 8.8 | 0.119 | <0.0001* |
| 4 | 8 | 0 | 37.5 | 0.25 | 48 | 2.1 | 12.5 | 0.112 | 0.108* |
| 12-mo. f/u | 192 | 74.7 | 76.8 | 0.64 | 220 | 47.3 | 24.6 | <0.0001 | <0.0001 |
‘Functioning within normal’ is defined as WSAS scores of less than 10 [Mundt et al. 2002]. Levels of treatment are as follows. Level 1: citalopram monotherapy; level 2: switching to sertraline, sustained release (SR) bupropion, extended release (XR) venlafaxine, or cognitive behavioral therapy (CBT); or augmenting with bupropion SR, buspirone; or CBT; level 3: switching to nortriptyline or mirtazapine; or augmenting with lithium or triiodothyronine (T3); level 4: switching to tranylcypromine; or switching to venlafaxine XR plus mirtazapine.
*
Fisher exact test used due to small sample size.
f/u, follow up; WSAS, Work and Social Adjustment Scale.